Lonza to acquire major biologics manufacturing facility
The new acquisition is set to boost Lonza’s large-scale biologics…
The new acquisition is set to boost Lonza’s large-scale biologics manufacturing capacity for mammalian therapeutics.
List view / Grid view
The new acquisition is set to boost Lonza’s large-scale biologics…
The new acquisition is set to boost Lonza’s large-scale biologics manufacturing capacity for mammalian therapeutics.
The large-scale commercial drug product fill and finish facility will…
The large-scale commercial drug product fill and finish facility will be built at Lonza’s existing site in Stein, Switzerland, with completion expected in 2026.